Climb Bio, Inc. $CLYM Shares Bought by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. boosted its position in shares of Climb Bio, Inc. (NASDAQ:CLYM) by 212.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 360,654 shares of the company’s stock after acquiring an additional 245,160 shares during the period. Nan Fung Trinity HK Ltd. owned 0.63% of Climb Bio worth $4,137,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in CLYM. State of Wyoming purchased a new stake in shares of Climb Bio in the third quarter worth $31,000. Legal & General Group Plc bought a new stake in shares of Climb Bio during the 2nd quarter valued at $45,000. Spark Investment Management LLC bought a new stake in shares of Climb Bio during the 2nd quarter valued at $177,000. Profund Advisors LLC purchased a new position in shares of Climb Bio during the 3rd quarter valued at $190,000. Finally, Bank of America Corp DE purchased a new position in shares of Climb Bio during the 2nd quarter valued at $335,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CLYM. Wall Street Zen raised shares of Climb Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. B. Riley Financial reissued a “buy” rating on shares of Climb Bio in a report on Friday, September 4th. Oppenheimer boosted their price objective on Climb Bio from $18.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, September 8th. Guggenheim reaffirmed a “buy” rating on shares of Climb Bio in a research note on Monday, October 26th. Finally, Wedbush increased their target price on Climb Bio from $25.00 to $27.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $28.14.

Climb Bio Stock Performance

CLYM stock opened at $10.87 on Friday. Climb Bio, Inc. has a one year low of $1.63 and a one year high of $18.33. The company’s fifty day moving average price is $11.66 and its 200-day moving average price is $10.60. The company has a market capitalization of $638.50 million, a PE ratio of -13.26 and a beta of 0.01.

Climb Bio (NASDAQ:CLYM) last issued its earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. On average, research analysts predict that Climb Bio, Inc. will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling

In other Climb Bio news, Director Stephen Thomas sold 100,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total value of $1,367,000.00. Following the sale, the director owned 467,969 shares in the company, valued at $6,397,136.23. The trade was a 17.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.60% of the stock is currently owned by insiders.

About Climb Bio

Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.